QSI stock forecast, quote, news & analysis
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies... Show more
Why Quantum-Si (QSI) Stock Is Up +37% in the Last 30 Days
Key Takeaways
- Quantum-Si (QSI) shares climbed roughly 37% over the trailing 30 days, rising from a close near $1.07 in late September to about $1.47 in late October.
- The move was driven primarily by development milestones for its next-generation Proteus single-molecule protein sequencing platform.
- Quantum-Si regained compliance with Nasdaq's $1.00 minimum-bid-price requirement after the stock closed above that threshold for 10 consecutive sessions.
- The company remains a pre-revenue, pre-profit development story: revenue totaled $344,000 in the second quarter of 2026, with significant operating losses.
- Management has shifted the anticipated commercial launch of Proteus to the second quarter of 2027, a key timeline investors continue to monitor.
- H.C. Wainwright reiterated a Buy rating and a $4.00 price target on the shares following the Proteus data releases.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the related pages to track the metrics behind the move.
- Readers interested in automated, signal-driven strategies can explore Trending AI Robots for a curated view of top-performing trading bots.
Quantum-Si (QSI) Company Overview and Market Position
Quantum-Si Incorporated is a life sciences technology company focused on proteomics, the study of the full set of proteins expressed within a cell. The company has developed a proprietary, semiconductor-chip-based single-molecule detection platform that enables next-generation protein sequencing (NGPS), an approach designed to read proteins in a massively parallel fashion rather than one at a time. Its commercial product line includes the Platinum and Platinum Pro benchtop sequencers, the Platinum Analysis Software, and associated consumable kits.
Quantum-Si's core thesis is that its technology can deliver faster, lower-cost, and more informative protein analysis than legacy mass spectrometry workflows, which are often expensive and complex. Investors follow the stock primarily for its development pipeline, led by the Proteus platform, which is intended to provide meaningfully higher sequencing output, greater sample throughput, and automated analysis relative to the current Platinum Pro system.
Quantum-Si (QSI) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, QSI shares advanced approximately 37%, moving from a closing price near $1.07 in late September to roughly $1.47 in late October. The rally was punctuated by sharp single-day gains on elevated volume, including a session in which trading volume reached roughly seven times the stock's 100-day average.
The move extended a broader recovery. For much of the summer, QSI traded below the $1.00 Nasdaq minimum-bid threshold, and shares were near $0.80 as recently as late August. The stock then more than doubled off those late-summer levels, reflecting renewed confidence in the Proteus development timeline and the company's regained exchange compliance. Despite the strong advance, the shares remain well below their 52-week high near $2.73.
What Drove QSI Stock Price in the Last 30 Days
The primary catalyst was a sequence of Proteus development updates. In late September, Quantum-Si presented interim data at the 2026 World HUPO Congress showing that Proteus delivered a median of roughly 30 times more sequencing alignments per chamber than Platinum Pro, a 4.8-times-lower median false discovery rate, and detection of cysteine and histidine residues that Platinum Pro could not identify. The announcement triggered a gain of more than 20% in a single session.
The momentum continued in October when the company disclosed that Proteus could now detect 19 of the 20 standard amino acids, up from 18 demonstrated earlier, and reaffirmed its expectation of detecting all 20 by the end of 2026. Shares jumped again on that news. The rally also coincided with Quantum-Si's confirmation in mid-October that it had regained Nasdaq minimum-bid-price compliance, removing a listing-related overhang that had pressured sentiment since a July deficiency notice. Founder Jonathan Rothberg publicly promoted the milestones, and H.C. Wainwright reiterated its Buy rating and $4.00 price target.
What Drove QSI Stock Performance Over the Last Quarter
The broader quarterly trend reflects a shift in investor focus from near-term financials to the Proteus commercialization roadmap. Earlier in 2026, Quantum-Si postponed Proteus's launch to the second quarter of 2027 and announced a roughly 20% workforce reduction expected to generate about $12 million in annualized operating expense savings. Those moves weighed on sentiment while the stock lingered below $1.00.
Subsequent development milestones reversed the narrative. Management reported that sequencing runs on multiple Proteus prototype systems were already meeting or exceeding Platinum Pro performance, and the company pointed to a substantial non-human proteomics market opportunity, including applications in agriculture, pathogen detection, and gene therapy. The regained Nasdaq compliance, combined with a rebound in speculative interest in single-molecule and AI-enabled life sciences tools, supported a sustained recovery into late October.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots from a platform offering hundreds of AI-driven bots that trade thousands of tickers. Only the top-performing and most relevant bots are highlighted, giving visitors a focused view of strategies that are currently standing out. These bots vary widely in trading style, timeframe, and performance metrics, so users can compare approaches that align with different goals and risk tolerances. For traders seeking a data-driven complement to their own research, exploring the section offers a practical way to see how algorithmic strategies are positioned across the market.
QSI Stock Forecast Drivers: What Investors Should Watch Next
The next major checkpoint is Quantum-Si's third-quarter 2026 financial results and business update, scheduled for early November, where management is expected to address Proteus development progress, cash runway, and the timeline for detecting all 20 amino acids. Investors should also monitor whether the company can hold its regained Nasdaq compliance and whether additional capital raises create dilution. Beyond the near term, the key variables are the completion of the all-20 amino acid demonstration, Proteus manufacturing readiness, and the commercial launch targeted for the second quarter of 2027. Because revenue remains minimal and the business is still loss-making, execution risk, cash consumption, and competitive dynamics in the proteomics tools market remain the central considerations for the stock's outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for QSI turns negative, indicating new downward trend
QSI saw its Momentum Indicator move below the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for QSI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 23 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 96 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices